Biotech Values

[iandy]

SGYP - Synergy Pharma (SGYP) Reports Positive Second Phase 3 Trial of Plecanatide in IBS-C

>Preliminary analysis of the data indicates that both plecanatide 3 mg and 6 mg doses met the study’s primary endpoint and showed statistical significance in the percentage of patients who were Overall Responders compared to placebo during the 12-week treatment period (30.2% in 3 mg and 29.5% in 6 mg dose groups compared to 17.8% in placebo; p<0.001 for 3 mg and p<0.001 for 6 mg).<

http://www.streetinsider.com/dr/news.php?id=12368649&gfv=1